Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 15;14(18):4476.
doi: 10.3390/cancers14184476.

Hemopatch to Prevent Lymphatic Leak after Robotic Prostatectomy and Pelvic Lymph Node Dissection: A Randomized Controlled Trial

Jeremy Yuen-Chun Teoh  1 , Alex Qinyang Liu  1 , Violet Wai-Fan Yuen  1 , Franco Pui-Tak Lai  1 , Steffi Kar-Kei Yuen  1 , Samson Yun-Sang Chan  1 , Julius Ho-Fai Wong  1 , Joseph Kai-Man Li  1 , Mandy Ho-Man Tam  1 , Peter Ka-Fung Chiu  1 , Samuel Chi-Hang Yee  1 , Chi-Fai Ng  1
Affiliations

Hemopatch to Prevent Lymphatic Leak after Robotic Prostatectomy and Pelvic Lymph Node Dissection: A Randomized Controlled Trial

Jeremy Yuen-Chun Teoh et al. Cancers (Basel). .

Abstract

This study investigates whether the application of Hemopatch, a novel hemostatic patch, could prevent lymphatic leak after robotic-assisted radical prostatectomy (RARP) and bilateral pelvic lymph node dissection (BPLND). This is a prospective, single-center, phase III randomized controlled trial investigating the efficacy of Hemopatch in preventing lymphatic leak after RARP and BPLND. Participants were randomized to receive RARP and BPLND, with or without the use of Hemopatch, with an allocation ratio of 1:1. The primary outcome is the total drain output volume. The secondary outcomes include blood loss, operative time, lymph node yield, duration of drainage, drain output per day, hospital stay, transfusion and 30-day complications. A total of 32 patients were recruited in the study. The Hemopatch group had a significantly lower median total drain output than the control group (35 mL vs. 180 mL, p = 0.022) and a significantly lower drain output volume per day compared to the control group (35 mL/day vs. 89 mL/day, p = 0.038). There was no significant difference in the other secondary outcomes. In conclusion, the application of Hemopatch in RARP and BPLND could reduce the total drain output volume and the drain output volume per day. The use of Hemopatch should be considered to prevent lymphatic leakage after RARP and BPLND.

Keywords: Hemopatch; lymphatic leak; pelvic lymph node dissection; prostate cancer; prostatectomy.

PubMed Disclaimer

Conflict of interest statement

The Hemopatch used in this study was sponsored by Baxter International Inc. The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Hemopatch placement position diagram. Ext. iliac art. = external iliac artery.
Figure 2
Figure 2
CONSORT flow diagram.
See this image and copyright information in PMC

References

    1. Mottet N., Bellmunt J., Bolla M., Briers E., Cumberbatch M.G., De Santis M., Fossati N., Gross T., Henry A.M., Joniau S., et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur. Urol. 2017;71:618–629. doi: 10.1016/j.eururo.2016.08.003. - DOI - PubMed
    1. Fossati N., Willemse P.-P.M., Van den Broeck T., van den Bergh R.C., Yuan C.Y., Briers E., Bellmunt J., Bolla M., Cornford P., De Santis M., et al. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. Eur. Urol. 2017;72:84–109. doi: 10.1016/j.eururo.2016.12.003. - DOI - PubMed
    1. Breslin J.W., Yang Y., Scallan J.P., Sweat R.S., Adderley S.P., Murfee W.L. Lymphatic vessel network structure and physiology. Compr. Physiol. 2018;9:207–299. - PMC - PubMed
    1. Gilbert D.R., Angell J., Abaza R. Evaluation of Absorbable Hemostatic Powder for Prevention of Lymphoceles Following Robotic Prostatectomy with Lymphadenectomy. Urology. 2016;98:75–80. doi: 10.1016/j.urology.2016.06.071. - DOI - PubMed
    1. Simonato A., Varca V., Esposito M., Venzano F., Carmignani G. The Use of a Surgical Patch in the Prevention of Lymphoceles after Extraperitoneal Pelvic Lymphadenectomy for Prostate Cancer: A Randomized Prospective Pilot Study. J. Urol. 2009;182:2285–2290. doi: 10.1016/j.juro.2009.07.033. - DOI - PubMed

LinkOut - more resources